Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (15093)	2/15/1998 2:13:00 AM
From: Torben Noerup Nielsen	Respond to of 32384

>If and when LGND presents data that 60+% of women had significant >shrinkage or total remission of their malignant breast cancer due to >targretin, LGND will be plastered on every magazine (TIME, NEWSWEEK, >etc) and on every nightly news program. That will surely help the >stock gain at least a point or two. :-) Not immediately; it would cause an immediate but temporary suspension of trading in the stock..... :-) It would also make the FDA give a whole new meaning to the term ''fast-track". Incidentally, Ligand would never need to pay for another trial with their own money...... :-) Even a significantly smaller percentage of complete cures - without the women having to undergo any kind of mastectomy or chemotherapy - would have pretty much the same effect. Bear in mind that so far, the safety profile of targreting appears good and the side effects fairly benign. This cannot be said of either mastectomies or chemotherapy. Cheers, Torben